TY  - ADVS
AU  - Deininger,Michael W.
TI  - CML: genetic paradigm of targeted therapy, part 1 of 2 
T2  - Cancer genetics,
PY  - 2015///
CY  - London
PB  - Henry Stewart Talks
KW  - Antineoplastic agents
KW  - Cancer
KW  - Genetic aspects
KW  - Chronic myeloid leukemia
KW  - Drug delivery systems
KW  - Protein kinases
KW  - Inhibitors
KW  - Antineoplastic Agents
KW  - pharmacology
KW  - Drug Delivery Systems
KW  - Fusion Proteins, bcr-abl
KW  - antagonists & inhibitors
KW  - imatinib
KW  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive
KW  - drug therapy
KW  - genetics
KW  - Molecular Targeted Therapy
KW  - methods
KW  - Philadelphia Chromosome
KW  - drug effects
KW  - Protein Kinase Inhibitors
KW  - Protein-Tyrosine Kinases
KW  - Translocation, Genetic
N1  - Animated audio-visual presentation with synchronized narration; Title from title frames; Contents: Typical clinical findings and phases of chronic myeloid leukaemia (CML) -- Philadelphia chromosome (juxtaposition & genomic anatomy BCR-ABL1) -- Target cells for transformation -- Molecular driver for pathogenesis (BCR-ABL1 tyrosine kinase) -- Imatinib (inhibitor of BCR-ABL1); Access restricted to subscribers
UR  - https://hstalks.com/bs/3131/
UR  - https://hstalks.com/bs/p/941/
ER  -